131968-76-8

Basic information

• Product Name: (+/-)-(3R,4S)-3-acetoxy-N-(4-methoxyphenyl)-4-phenylazetidin-2-one
• CAS NO: 131968-76-8
• Molecular Weight: 311.337
• Mol File: 131968-76-8.mol
• Article Data: 17

Chemical Properties

• CAS DataBase Reference: (+/-)-(3R,4S)-3-acetoxy-N-(4-methoxyphenyl)-4-phenylazetidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-(3R,4S)-3-acetoxy-N-(4-methoxyphenyl)-4-phenylazetidin-2-one(131968-76-8)
• EPA Substance Registry System: (+/-)-(3R,4S)-3-acetoxy-N-(4-methoxyphenyl)-4-phenylazetidin-2-one(131968-76-8)

Safety Data

• Hazardous Substances Data: 131968-76-8(Hazardous Substances Data)

Upstream product

• 783-08-4 [4-(benzylideneamino)phenyl]methanol 
• 141685-06-5 S-2-pyridyl acetoxythioacetate 
• 13831-31-7 Acetoxyacetyl chloride 
• 13831-30-6 acetoxyacetic acid 
• 1613-90-7 4-methoxy-N-[(E)-phenylmethylidene]aniline 
• 100-52-7 benzaldehyde 
• 104-94-9 4-methoxy-aniline 
• 40339-42-2 4-methoxy-N-[(1Z)-phenylmethylene]aniline 

Downstream Products

• 94612-33-6 1-(4-methoxyphenyl)-4-phenylazetidine-2,3-dione 
• 133066-59-8 (±)-cis-3-acetyloxy-4-phenylazetidin-2-one 

Relevant articles and documents

Unprecedented stereoselectivity in the Staudinger reaction with polycyclic aromatic imines

Cycloaddition of imines derived from polycyclic aromatic amines with acid chloride (or equivalent) in the presence of triethylamine at -78°C to room temperature unexpectedly produced trans-β-lactams. (C) 2000 Elsevier Science Ltd.

Synthesis and biological evaluation of novel larotaxel analogues

Taxoids are a class of successful drugs and have been successfully used in chemotherapy for a variety of cancer types. However, despite the hope and promises that these taxoids have engendered, their utility is hampered by some clinic limitations. Extensive structure-activity relationship (SAR) studies of toxoids have been performed in many different laboratories. Whereas, SAR studies that based on the new-generation toxoid, larotaxel, have not been reported yet. In view of the advantages in preclinical and clinical data of larotaxel over former toxoids, new taxoids that strategicly modified at the C3’/C3′-N and C2 positions of larotaxel were designed, semi-synthesized, and examined for their potency and efficacy in vitro. As a result, it has been shown that the majority of these larotaxel analogues are exceptionally potent against both drug-sensitive tumor cells and tumor cells with drug resistance arising from P-glycoprotein over expression. Further in vivo antitumor efficacies investigations revealed A2 might be a potent antitumor drug candidate for further preclinical evaluation.

Paclitaxel Biosynthesis: Adenylation and Thiolation Domains of an NRPS TycA PheAT Module Produce Various Arylisoserine CoA Thioesters

Structure-activity relationship studies show that the phenylisoserinyl moiety of paclitaxel (Taxol) is largely necessary for the effective anticancer activity. Several paclitaxel analogues with a variant isoserinyl side chain have improved pharmaceutical